Primmune Therapeutics is developing an orally administered agonist to stimulate innate immunity in cancer immunotherapy. This innate immunity stimulator is highly complementary to and is expected to be useful in combination with other immunotherapies including (i) checkpoint inhibitors and related agents (e.g., IDO, tyrosine kinase inhibitors and other), (ii) antibody and antibody-like therapeutics, (iii) therapeutic … Continue reading Primmune Therapeutics, Inc.
TarGead Sciences, Inc. is a newly launched biopharmaceutical company founded by leading scientists from University of South California and Amgen, Inc. TarGead Sciences employs a proprietary chemoproteomic platform to discover novel therapeutics for the treatment of diverse diseases such as cancer, metabolic disorders, and osteoporosis. TarGead Sciences, Inc. is a newly launched biopharmaceutical company founded … Continue reading TarGead Sciences, Inc.
System 1 Biosciences is a San Francisco-based startup revolutionizing drug discovery.
Synergys Biotherapeutic is pursuing two divergent strategies to develop Anti-vasculogenic Antibody Therapeutics that could alleviate shortcomings of the current cancer-targeted anti-angiogenic drugs. Many aggressive tumors, especially Triple Negative Brea
STATegics, Inc. is a privately-held biopharmaceutical company in South San Francisco, CA, committed to the discovery and development of small molecule modulators of cytokine receptors. The company’s lead programs are focused on small molecule agonists of erythropoietin (EPO) and thrombopoietin (TPO) receptors for the treatment of central nervous system diseases and thrombocytopenia, respectively. STATegics’ lead … Continue reading STATegics, Inc.
Scaled Biolabs is accelerating biologic, gene, and cell therapies using smart microfluidic chips. Thousands of cell experiments can be parallelized and automated on their lab-on-a-chip system, increasing throughput, precision, economy, and insight that can lead to dramatic innovations in organogenesis, fermentation condition optimization and therapeutic production.
R2M Pharma is a start up biotech company working on research efforts to optimize compounds to go into clinical trials. We work in partnership with ongoing projects. The company started operations in March of 2017.
Psynthesys is liberating Biopharma from unnecessarily cumbersome information trafficking systems presently being relied on in clinical trials for data integrity in patient care. Our technology assists clinical investigators in day to day processes, creating an essential focus on the unique information use and exchange contexts posed in clinical operations. Psynthesys’ interactive information logic environment is … Continue reading Psynthesys, Inc